| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 23.977 | 33.425 | 26.675 | 49.000 | 45.570 | 238.738 | 961.768 | 263.228 | 299.426 | 107.940 |
| Total Income - EUR | 23.977 | 33.425 | 26.675 | 49.000 | 45.570 | 271.026 | 882.312 | 263.228 | 300.707 | 114.515 |
| Total Expenses - EUR | 3.467 | 17.078 | 8.832 | 56.303 | 21.243 | 142.032 | 500.691 | 155.423 | 154.689 | 69.412 |
| Gross Profit/Loss - EUR | 20.510 | 16.347 | 17.843 | -7.303 | 24.327 | 128.993 | 381.621 | 107.805 | 146.018 | 45.102 |
| Net Profit/Loss - EUR | 19.790 | 15.344 | 17.043 | -8.171 | 23.871 | 126.470 | 374.310 | 105.882 | 143.840 | 43.207 |
| Employees | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Metaxacip S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 116.521 | 121.878 | 114.131 | 126.352 | 181.691 | 201.679 | 590.337 | 649.725 | 642.578 | 677.629 |
| Current Assets | 249.498 | 224.569 | 220.333 | 225.039 | 237.480 | 288.159 | 278.302 | 498.584 | 652.233 | 777.286 |
| Inventories | 9.330 | 1 | 1 | 2.161 | 17.075 | 17.322 | 65.346 | 236.507 | 275.010 | 281.723 |
| Receivables | 239.906 | 213.878 | 216.938 | 219.035 | 217.989 | 258.572 | 174.363 | 257.671 | 373.262 | 494.353 |
| Cash | 262 | 10.690 | 3.395 | 3.844 | 2.415 | 12.265 | 38.593 | 4.406 | 3.961 | 1.211 |
| Shareholders Funds | 55.593 | 74.304 | 90.090 | 80.265 | 124.033 | 236.438 | 605.504 | 713.265 | 854.942 | 893.371 |
| Social Capital | 45 | 45 | 44 | 43 | 63 | 62 | 61 | 61 | 61 | 60 |
| Debts | 310.426 | 272.143 | 244.374 | 271.126 | 295.139 | 253.400 | 253.942 | 403.744 | 427.694 | 556.111 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 9.193 | 31.300 | 12.175 | 5.482 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4673 - 4673" | |||||||||
| CAEN Financial Year |
4673
|
|||||||||
Comments - Metaxacip S.r.l.